AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $138,288,822 | -1.5% | 11,372,436 | +1.7% | 0.01% | +14.3% |
| Q2 2023 | $140,411,280 | +13.7% | 11,179,242 | +0.4% | 0.01% | 0.0% |
| Q1 2023 | $123,441,421 | -58.2% | 11,130,885 | -54.0% | 0.01% | -22.2% |
| Q4 2022 | $295,136,188 | +135.1% | 24,171,678 | +101.1% | 0.01% | +12.5% |
| Q3 2022 | $125,512,000 | -16.0% | 12,022,212 | -13.6% | 0.01% | -11.1% |
| Q2 2022 | $149,483,000 | +32.3% | 13,918,315 | +16.6% | 0.01% | +50.0% |
| Q1 2022 | $113,020,000 | -6.8% | 11,934,563 | +13.6% | 0.01% | 0.0% |
| Q4 2021 | $121,299,000 | +26.8% | 10,502,065 | +4.9% | 0.01% | +20.0% |
| Q3 2021 | $95,650,000 | +5.2% | 10,015,730 | +6.1% | 0.01% | 0.0% |
| Q2 2021 | $90,965,000 | -3.5% | 9,436,249 | -1.1% | 0.01% | 0.0% |
| Q1 2021 | $94,225,000 | -48.4% | 9,536,942 | +20.6% | 0.01% | -54.5% |
| Q4 2020 | $182,628,000 | +44.9% | 7,909,391 | -11.4% | 0.01% | +22.2% |
| Q3 2020 | $126,078,000 | -18.7% | 8,929,059 | -13.2% | 0.01% | -18.2% |
| Q2 2020 | $155,075,000 | +50.8% | 10,283,507 | -7.6% | 0.01% | +22.2% |
| Q1 2020 | $102,833,000 | -4.0% | 11,129,151 | +1.2% | 0.01% | +28.6% |
| Q4 2019 | $107,108,000 | +15.3% | 10,996,724 | -5.0% | 0.01% | 0.0% |
| Q3 2019 | $92,881,000 | -24.0% | 11,581,181 | +18.2% | 0.01% | -22.2% |
| Q2 2019 | $122,279,000 | +3.8% | 9,797,979 | +13.1% | 0.01% | 0.0% |
| Q1 2019 | $117,823,000 | +43.8% | 8,663,483 | +1.3% | 0.01% | +28.6% |
| Q4 2018 | $81,953,000 | -28.6% | 8,554,552 | -9.9% | 0.01% | -22.2% |
| Q3 2018 | $114,750,000 | -7.7% | 9,491,113 | +19.2% | 0.01% | -10.0% |
| Q2 2018 | $124,370,000 | -3.3% | 7,962,456 | -6.9% | 0.01% | -9.1% |
| Q1 2018 | $128,586,000 | +14.0% | 8,549,577 | +9.1% | 0.01% | +22.2% |
| Q4 2017 | $112,794,000 | -8.2% | 7,838,452 | -3.8% | 0.01% | -18.2% |
| Q3 2017 | $122,917,000 | +107.2% | 8,151,091 | +38.3% | 0.01% | +120.0% |
| Q2 2017 | $59,332,000 | +44.3% | 5,892,564 | +2.2% | 0.01% | +25.0% |
| Q1 2017 | $41,118,000 | +44.9% | 5,766,929 | +0.9% | 0.00% | +33.3% |
| Q4 2016 | $28,386,000 | -24.7% | 5,715,947 | +12.2% | 0.00% | -25.0% |
| Q3 2016 | $37,694,000 | +54.1% | 5,093,598 | +13.7% | 0.00% | +33.3% |
| Q2 2016 | $24,463,000 | -24.2% | 4,480,616 | +17.3% | 0.00% | 0.0% |
| Q1 2016 | $32,271,000 | -35.5% | 3,819,430 | -25.9% | 0.00% | -40.0% |
| Q4 2015 | $50,024,000 | +5.6% | 5,156,858 | +52.2% | 0.01% | -16.7% |
| Q3 2015 | $47,390,000 | +2.2% | 3,387,339 | +3.4% | 0.01% | +20.0% |
| Q2 2015 | $46,369,000 | +75.3% | 3,277,039 | +34.8% | 0.01% | +66.7% |
| Q1 2015 | $26,452,000 | +48.9% | 2,431,229 | +13.9% | 0.00% | +50.0% |
| Q4 2014 | $17,761,000 | +9822.3% | 2,134,791 | +7028.3% | 0.00% | – |
| Q3 2014 | $179,000 | +84.5% | 29,948 | +3.8% | 0.00% | – |
| Q2 2014 | $97,000 | -89.1% | 28,848 | -93.3% | 0.00% | – |
| Q1 2014 | $894,000 | -59.6% | 432,456 | -50.8% | 0.00% | – |
| Q4 2013 | $2,211,000 | +122.9% | 879,201 | +105.1% | 0.00% | – |
| Q3 2013 | $992,000 | -0.8% | 428,602 | -0.3% | 0.00% | – |
| Q2 2013 | $1,000,000 | – | 429,689 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |